Stifel Initiates Coverage On Regenxbio with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy has initiated coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and a price target of $35.
November 01, 2023 | 9:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on Regenxbio with a Buy rating and a price target of $35, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Stifel's Buy rating and price target of $35 for Regenxbio could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100